The manipulation of miRNA-gene regulatory networks by KSHV induces endothelial cell motility.

miRNAs have emerged as master regulators of cancer-related events. miRNA dysregulation also occurs in Kaposi sarcoma (KS). Exploring the roles of KS-associated miRNAs should help to identify novel angiogenesis and lymphangiogenesis pathways. In the present study, we show that Kaposi sarcoma-associated herpesvirus (KSHV), the etiological agent of KS, induces global miRNA changes in lymphatic endothelial cells (LECs). Specifically, the miR-221/miR-222 cluster is down-regulated, whereas miR-31 is up-regulated. Both latent nuclear antigen (LANA) and Kaposin B repress the expression of the miR-221/miR-222 cluster, which results in an increase of endothelial cell (EC) migration. In contrast, miR-31 stimulates EC migration, so depletion of miR-31 in KSHV-transformed ECs reduces cell motility. Analysis of the putative miRNA targets among KSHV-affected genes showed that ETS2 and ETS1 are the downstream targets of miR-221 and miR-222, respectively. FAT4 is one of the direct targets of miR-31. Overexpression of ETS1 or ETS2 alone is sufficient to induce EC migration, whereas a reduction in FAT4 enhances EC motility. Our results show that KSHV regulates multiple miRNA-mRNA networks to enhance EC motility, which eventually contributes to KS progression by promoting the spread of malignant KS progenitor cells. Targeting KSHV-regulated miRNAs or genes might allow the development of novel therapeutic strategies that induce angiogenesis or allow the treatment of pathogenic (lymph)angiogenesis.

[1]  Shusheng Wang,et al.  AngiomiRs--key regulators of angiogenesis. , 2009, Current opinion in genetics & development.

[2]  D. Dittmer,et al.  Long-Term-Infected Telomerase-Immortalized Endothelial Cells: a Model for Kaposi's Sarcoma-Associated Herpesvirus Latency In Vitro and In Vivo , 2006, Journal of Virology.

[3]  C. Croce,et al.  miRNAs, Cancer, and Stem Cell Division , 2005, Cell.

[4]  J. Vieira,et al.  Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. , 2004, Virology.

[5]  Thomas Ruzicka,et al.  Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. , 2002, The Lancet. Infectious diseases.

[6]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[7]  S. Henderson,et al.  Kaposi sarcoma herpesvirus–induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma , 2004, Nature Genetics.

[8]  C. Lim,et al.  Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits its transcriptional activation activity. , 2000, The Journal of general virology.

[9]  Chao Qi,et al.  Identification of Fat4 as a candidate tumor suppressor gene in breast cancers , 2009, International journal of cancer.

[10]  Shou-Jiang Gao,et al.  Kaposi's Sarcoma-Associated Herpesvirus Infection Promotes Invasion of Primary Human Umbilical Vein Endothelial Cells by Inducing Matrix Metalloproteinases , 2007, Journal of Virology.

[11]  M. Takeichi,et al.  New insights into Fat cadherins , 2005, Journal of Cell Science.

[12]  Blossom Damania,et al.  Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. , 2009, Blood.

[13]  C. Boshoff,et al.  Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. , 2007, Blood.

[14]  Michael C. Ostrowski,et al.  Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. , 2009, Blood.

[15]  D. Ganem,et al.  The Kaposin B Protein of KSHV Activates the p38/MK2 Pathway and Stabilizes Cytokine mRNAs , 2005, Science.

[16]  Jay W. Shin,et al.  miR-31 Functions as a Negative Regulator of Lymphatic Vascular Lineage-Specific Differentiation In Vitro and Vascular Development In Vivo , 2010, Molecular and Cellular Biology.

[17]  Laura Mariani,et al.  MicroRNAs modulate the angiogenic properties of HUVECs. , 2006, Blood.

[18]  P. Chaudhary,et al.  Kaposi's sarcoma associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a , 2009, Oncogene.

[19]  Jordan S. Pober,et al.  Dicer Dependent MicroRNAs Regulate Gene Expression and Functions in Human Endothelial Cells , 2007, Circulation research.

[20]  Jay W. Shin,et al.  Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirus , 2004, Nature Genetics.

[21]  A. Gessain,et al.  Spindle cells and their role in Kaposi's sarcoma. , 2005, The international journal of biochemistry & cell biology.

[22]  Zongguang Zhou,et al.  Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells , 2010, BMC Cancer.

[23]  Ling Wang,et al.  Pre-Micro RNA Signatures Delineate Stages of Endothelial Cell Transformation in Kaposi Sarcoma , 2009, PLoS pathogens.

[24]  M. Detmar,et al.  Prox1, master regulator of the lymphatic vasculature phenotype , 2003, Cell and Tissue Research.

[25]  R. Vyzula,et al.  Altered Expression of miR-21, miR-31, miR-143 and miR-145 Is Related to Clinicopathologic Features of Colorectal Cancer , 2008, Oncology.

[26]  Jürgen Dittmer,et al.  Molecular Cancer BioMed Central Review The Biology of the Ets1 Proto-Oncogene , 2003 .

[27]  Bing Zhang,et al.  WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..

[28]  A. Griffioen,et al.  MicroRNAs in the tumor endothelium: novel controls on the angioregulatory switchboard. , 2010, Biochimica et biophysica acta.

[29]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[30]  S. Anand,et al.  MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis , 2010, Nature Medicine.

[31]  S. Borah,et al.  Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus Up-Regulates Transcription of Human Telomerase Reverse Transcriptase Promoter through Interaction with Transcription Factor Sp1 , 2004, Journal of Virology.

[32]  Gene Ontology Consortium.  The Gene Ontology (GO) database and informatics resource , 2003 .

[33]  Manfred Gessler,et al.  Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease , 2008, Nature Genetics.

[34]  Frances Gotch,et al.  miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator , 2010, Nature Cell Biology.

[35]  A. Moses,et al.  Endothelial cell- and lymphocyte-based in vitro systems for understanding KSHV biology. , 2007, Current topics in microbiology and immunology.

[36]  K. Livak,et al.  Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.

[37]  L. Cavanna,et al.  Human herpesvirus 8-associated primary effusion lymphoma in HIV--patients: a clinicopidemiologic variant resembling classic Kaposi's sarcoma. , 2002, Haematologica.

[38]  Lijun Wu,et al.  A Complex Translational Program Generates Multiple Novel Proteins from the Latently Expressed Kaposin (K12) Locus of Kaposi’s Sarcoma-Associated Herpesvirus , 1999, Journal of Virology.

[39]  C. Croce,et al.  MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. , 2010, Journal of the National Cancer Institute.

[40]  Shing-Jyh Chang,et al.  The M Type K15 Protein of Kaposi's Sarcoma-Associated Herpesvirus Regulates MicroRNA Expression via Its SH2-Binding Motif To Induce Cell Migration and Invasion , 2008, Journal of Virology.

[41]  D. Sage,et al.  Characterization of Kaposi sarcoma-associated herpesvirus/human herpesvirus-8 infection of human vascular endothelial cells: early events. , 2002, Blood.

[42]  Y. Suárez,et al.  Cutting Edge: TNF-Induced MicroRNAs Regulate TNF-Induced Expression of E-Selectin and Intercellular Adhesion Molecule-1 on Human Endothelial Cells: Feedback Control of Inflammation , 2009, The Journal of Immunology.

[43]  Stefanie Dimmeler,et al.  Role of microRNAs in vascular diseases, inflammation, and angiogenesis. , 2008, Cardiovascular research.

[44]  Robert A. Weinberg,et al.  A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .

[45]  P. Oettgen,et al.  Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. , 2006, Blood.

[46]  Paul Kellam,et al.  KSHV-encoded miRNAs target MAF to induce endothelial cell reprogramming. , 2010, Genes & development.

[47]  N. Inoue,et al.  Inhibition of Infection and Replication of Human Herpesvirus 8 in Microvascular Endothelial Cells by Alpha Interferon and Phosphonoformic Acid , 2004, Journal of Virology.

[48]  R. Swerlick,et al.  HMEC-1: establishment of an immortalized human microvascular endothelial cell line. , 1992, The Journal of investigative dermatology.

[49]  J. Bischoff,et al.  Angiostatin upregulates E-selectin in proliferating endothelial cells. , 1998, Biochemical and biophysical research communications.